Stavudine

Confirm delete?

Stavudine

Zoom

Cat No: 14975

Stavudine is an inhibitor of HIV reverse transcriptase and a derivative of the nucleoside thymidine (Item No. 20519).{53215} It inhibits HIV-1 replication in human peripheral blood mononuclear cells (PBMCs; EC50 = 8.8 nM). Stavudine reduces the synthe...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2',3'-didehydro-3'-deoxy-thymidine

Correlated keywords:

132425-31-1 Avostav BMY27857 D-4T Melxicap NSC163661 Sanilvudine Staduvine Stag Stavir Virostav Zerit PBMC MT4 HIV2 anti-retroviral HIV1 DHT

Product Overview:
Stavudine is an inhibitor of HIV reverse transcriptase and a derivative of the nucleoside thymidine (Item No. 20519).{53215} It inhibits HIV-1 replication in human peripheral blood mononuclear cells (PBMCs; EC50 = 8.8 nM). Stavudine reduces the synthesis of HIV-specific antigen in MT-4 cells when used at concentrations ranging from 0.1 to 10 µg/ml and reduces HIV-induced plaque formation in MT-4 cells at 0.05 µg/ml.{29420} It reduces plasma- and cell-associated viral load in macaques infected with a highly pathogenic isolate of HIV-2.{53216} Stavudine induces sustained hind paw mechanical allodynia in a rat model of antiretroviral toxic neuropathy (ATN) when administered at a dose of 75 mg/kg twice weekly for five consecutive doses for a cumulative dose of 375 mg/kg.{53217} Formulations containing stavudine, in combination with other antiretrovirals, have been used in the treatment of HIV-1 infection.

Size	100 mg
Shipping	dry ice
CAS Number	3056-17-5
Molecular Formula	C₁₀H₁₂N₂O₄
SMILES	OC[C@H]1O[C@@H](N2C(NC(C(C)=C2)=O)=O)C=C1
Molecular Weight	224,2
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2922.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.